

Bristol-Myers Squibb Position Statement on Climate Change

We are committed to preserving natural resources, minimizing the environmental impact of our operations, and reducing greenhouse gas (GHG) emissions. The United Nations Framework Convention on Climate Change acknowledged that climate systems can be affected by GHGs.

We have had management programs in place to reduce energy and greenhouse gas emissions globally since the 1990s. Our Sustainability 2020 Goals include a target to reduce GHG emissions by 5 percent on an absolute basis versus a 2015 baseline. We use renewable energy where technically and economically practical. We publicly report on our progress toward our Sustainability goals annually.

We support voluntary reporting of GHG emissions, fund energy efficiency and GHG reduction projects, use high-efficiency and innovative technologies, select fleet vehicles to reduce fuel emissions, reduce travel through use of video/teleconferencing, and participate in multi-stakeholder initiatives. We also collaborate on best practices and energy strategy within our industry and across industries, and participate on the EPA Energy Star Pharmaceutical Focus Group. We report our emissions through the Carbon Disclosure Project and encourage our suppliers to do the same. Our programs are aligned with the expectations of COP21 including a commitment, a focus on GHGs, target setting and reporting.

Climate change poses potential commercial risks for our company and the pharmaceutical industry in general. We have commercial operations worldwide, exposing us to diverse climates and regulatory environments. Contingency plans are in place to mitigate potential risks associated with operating globally, including supply chain, weather patterns, regulations, and energy costs.

Our long-term ability to operate and provide patients with the medicines they need is at risk without reliable sources of energy and clean water. We have therefore identified these as key sustainability issues for our company and have implemented programs to maximize our efficient use of these resources. The ability of our global operations to manage energy efficiently, reduce operating costs and GHG emissions, leverage innovative technologies and quickly adapt to changing physical conditions resulting from climate change may produce sources of competitive advantage.

Health care needs may also change as a result of regional climate changes, potentially resulting in shifting or new markets for medicines. Climate change may result in outbreak or spread of diseases, and possibly a need to develop new medicines to address unmet needs.

We closely monitor regulatory developments worldwide. Our operations will continue to be impacted by various elements of the second round of country commitments at COP21 under the Kyoto Protocol including national emission allocation plans, taxes, and regulatory standards. We support science-based action that provides secure, affordable energy supplies and includes economic incentives for new technologies.

We believe addressing climate change is a shared responsibility among industry and governments. Although the pharmaceutical industry contributes fewer GHGs than other industrial sectors, we will continue our efforts as part of environmental stewardship.